The European Food Safety Authority (EFSA) has published an opinion that Arla Foods Ingredients’ Peptigen® IF-3080 (protein hydrolysate) is safe and suitable for use in infant formula and follow-on formula products in the EU.
The news follows EU regulations, which state that from February 22, 2022, the nutritional safety and suitability of all protein hydrolysates used in the manufacture of infant milk formula and follow-on formula in the EU would need to be evaluated. To date, Arla Foods Ingredients’ Peptigen® IF-3080 is one of only a few milk protein hydrolysate ingredients to receive a positive EFSA opinion. Those which are not approved are removed from the market.
The European Commission is expected to include Peptigen® IF-3080 in the Commission Delegated Regulation (EU) 2016/17 within the coming 12 months. Thereby, Arla Foods Ingredients’ Peptigen® IF-3080 will be approved for use in infant and follow-on formulas sold in the EU. Until then, Arla Foods Ingredients can supply Peptigen® IF-3080 to its EU customers for the development of infant formula brands, which can be prepared for launch.
Anders Steen Jorgensen, Head of SBU Pediatric, Arla Foods Ingredients, said: “We are delighted by this opinion, which supports our reputation for having the industry’s highest levels of quality, innovation and food safety.”
